First-in-human study of REGN3767 (R3767), a human LAG-3 monoclonal antibody (mAb), ± cemiplimab in patients (pts) with advanced malignancies.

出版年份 2019 全文链接

标题

作者

关键词

出版物

Volume 37, Issue 15_suppl, Pages 2508-2508

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2019-05-27

DOI

10.1200/jco.2019.37.15_suppl.2508

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now